Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
Conditions
- ALK Positive Non-small Cell Lung Cancer
Interventions
- DRUG: Lorlatinib
- DRUG: sacituzumab tirumotecan plus lorlatinib
Sponsor
Guangdong Association of Clinical Trials